Combined Oxidative Phosphorylation Deficiency Caused by Mutation in MRPL3

Combined oxidative phosphorylation deficiency caused by mutation in MRPL3 is a very rare genetic disease. It is a type of mitochondrial disease. In this condition, the tiny “power stations” inside cells, called mitochondria, cannot make enough energy. This happens because the MRPL3 gene, which helps build part of the mitochondrial ribosome (the protein-making machine in mitochondria), does not work properly. [1][2] The full medical name for this specific condition is Combined Oxidative Phosphorylation Deficiency 9 (COXPD9). It is caused by harmful changes (mutations) in both copies of the MRPL3 gene. Children usually get one changed copy from each parent. This is called autosomal recessive inheritance. [1][3]

Combined oxidative phosphorylation deficiency caused by mutation in MRPL3 is a very rare inherited mitochondrial disease. It is also called combined oxidative phosphorylation deficiency 9 (COXPD9). In this condition, changes in the MRPL3 gene damage the tiny “power stations” of the cell (mitochondria), so the cell cannot make enough energy using the oxidative phosphorylation (OXPHOS) system. This mainly affects high-energy organs such as the heart, liver, muscles and brain, leading to poor growth, feeding problems, enlarged heart, enlarged liver and delayed development, often starting in early infancy.

COXPD9 is usually inherited in an autosomal recessive way. This means a child is affected if they receive one faulty MRPL3 copy from each parent. Parents are usually healthy carriers. Because mitochondria are needed in every cell, symptoms can be “multi-system” and may progress over time. Sadly, in some reported children the disease has been life-limiting, but the exact course can vary between families and depends on how strongly the gene change affects mitochondrial function.

---

Genetics (MRPL3 Mutation)

The MRPL3 gene gives instructions to make a protein called mitochondrial ribosomal protein L3, which is part of the large subunit of the mitochondrial ribosome. Mitochondrial ribosomes are needed to build many proteins that sit inside the respiratory chain complexes (complexes I–V) that carry out oxidative phosphorylation. When MRPL3 is mutated, the mitochondrial ribosome does not work properly, so these key proteins cannot be made in normal amounts.

Because the mitochondrial ribosome does not work well, the cell cannot make some important proteins that are needed for the respiratory chain complexes (complex I, III, IV and V). These complexes are used in oxidative phosphorylation, the main energy-making pathway in mitochondria. When they are weak, cells do not make enough ATP (the main energy “coin” of the body). This causes serious problems in organs that need a lot of energy, such as the heart, liver, brain and muscles. [2][4]

Babies with this disease often have poor feeding, do not gain weight well (failure to thrive), may have enlarged liver (hepatomegaly), thick heart muscle (hypertrophic cardiomyopathy), and slow development of movement and thinking skills (psychomotor retardation). Sadly, many reported children become very sick in early life, and some die in infancy. [3][5]

Other names

Doctors and researchers use several different names for the same disease. These names may appear in genetic reports or medical articles. [1][2]

• Combined Oxidative Phosphorylation Deficiency 9

• COXPD9

• Combined Oxidative Phosphorylation Defect Type 9

• Combined oxidative phosphorylation deficiency caused by mutation in MRPL3

• MRPL3-related combined oxidative phosphorylation deficiency

• Mitochondrial disease due to MRPL3 mutation

All these names describe the same basic problem: a mitochondrial energy-making defect caused by harmful changes in the MRPL3 gene. [1][4]

Types

There is only one official genetic “type” linked to MRPL3: Combined oxidative phosphorylation deficiency 9 (COXPD9). However, doctors sometimes talk about sub-types based on how the disease looks in the patient. [1][3]

Here are useful “clinical types” in list form:

• Classic severe infantile type
  Babies show symptoms in the first months of life. They have poor feeding, failure to thrive, enlarged liver, thick heart muscle and serious developmental delay. The disease is usually fast and very serious. [1][2]

• Cardiac-predominant type
  In some children, heart disease (especially hypertrophic cardiomyopathy) is the main problem. They may have fast breathing, poor feeding, sweating with feeds, and signs of heart failure, while other organs seem less affected at first. [2][4]

• Hepatic-neurologic type
  In this type, liver problems (enlarged liver, abnormal liver tests) and brain problems (developmental delay, low muscle tone, seizures) are both strong features. The heart may also be affected, but sometimes less obviously at the beginning. [3][5]

• Multisystem type
  Many children show problems in several organs at the same time: heart, liver, muscles, brain, and sometimes kidneys or blood. This is common in mitochondrial diseases because energy is needed everywhere in the body. [1][4]

These “types” are ways to describe patterns. They are not separate genetic diseases. The same MRPL3 mutation can sometimes cause different patterns even in children from the same family. [2][3]

Causes (Mechanisms and contributing factors)

In this disease, the main cause is pathogenic (harmful) mutations in the MRPL3 gene. The other “causes” below are supporting mechanisms or factors that explain how this gene change leads to disease or makes it worse. [1][2]

1. Biallelic MRPL3 gene mutation
   The child inherits one faulty MRPL3 gene from each parent. Both copies in the child’s cells are changed, so MRPL3 protein cannot work normally. This is called autosomal recessive inheritance. [1][3]

2. Missense mutations in MRPL3
   A missense mutation changes one amino acid in the MRPL3 protein. This may change the protein’s shape so it cannot fit properly into the mitochondrial ribosome. Even a single change can greatly disturb energy production. [2][4]

3. Splice-site mutations in MRPL3
   Some mutations affect the places where the gene is “cut and pasted” (splicing). This can produce a very short or abnormal MRPL3 protein, or no useful protein at all. This strongly reduces mitochondrial translation. [3][5]

4. Nonsense or frameshift MRPL3 mutations
   These mutations create a “stop” signal too early or shift the reading frame, so the protein is cut short. A short MRPL3 protein usually cannot build a stable ribosome, leading to severe disease. [1][2]

5. Defective mitochondrial ribosome assembly
   MRPL3 is part of the large 39S subunit of the mitochondrial ribosome. When MRPL3 is faulty, the ribosome cannot assemble correctly. Without a proper ribosome, the mitochondria cannot make key proteins needed for energy production. [1][4]

6. Impaired mitochondrial translation
   Translation is the process of building proteins from RNA. In this disease, mitochondrial translation is impaired, so the mitochondria make less of the proteins that form the respiratory chain complexes. [2][5]

7. Combined respiratory chain complex deficiency
   Because many mitochondrial proteins are missing or low, several complexes (I, III, IV, and V) in the respiratory chain do not work well. This is why the disease is called “combined oxidative phosphorylation deficiency.” [1][3]

8. Reduced ATP production
   ATP is the main energy molecule. When the respiratory chain is weak, ATP production falls. Organs that need a lot of energy, such as the heart and brain, suffer the most, leading to organ failure. [2][4]

9. Increased lactic acid (lactic acidosis)
   When cells cannot make enough energy with oxygen (aerobic), they switch to less efficient pathways that produce lactic acid. Lactic acid builds up in the blood and tissues, causing lactic acidosis, which can make children very sick. [3][5]

10. Oxidative stress and reactive oxygen species (ROS)
    Damaged mitochondria can leak more reactive oxygen molecules. These “free radicals” can harm proteins, fats and DNA, worsening cell injury and speeding up organ damage. [4][6]

11. Energy failure in heart muscle
    The heart beats nonstop and needs constant energy. Low ATP in heart cells can cause thickening of the heart muscle (hypertrophic cardiomyopathy), weak pumping and heart failure. [1][3]

12. Energy failure in liver cells
    The liver also needs a lot of energy. Mitochondrial failure can cause enlarged liver, poor processing of nutrients, clotting problems and abnormal liver blood tests. [2][4]

13. Energy failure in brain and nerves
    Brain cells are very sensitive to low energy. This can cause developmental delay, low muscle tone, seizures and later loss of skills. [2][5]

14. Energy failure in skeletal muscles
    Muscles may become weak and floppy because they cannot make enough ATP. Babies may have trouble holding up their head, sitting or moving normally. [3][4]

15. Modifier genes and background mitochondrial function
    Other genes in the nuclear DNA or mitochondrial DNA may change how severe the disease is. Some children may have slightly better mitochondrial reserve, while others have very low reserve. This can modify the clinical picture. [4][6]

16. Intercurrent infections
    Infections such as common colds or stomach bugs put extra stress on the body. A child whose mitochondria are already weak may decompensate (suddenly get worse) during or after an infection. The infection does not cause the mutation, but it can trigger a crisis. [3][5]

17. Fever and metabolic stress
    Fever increases energy needs. In mitochondrial disease, the body cannot respond well to higher demand, which can lead to worsening lactic acidosis, seizures, or heart failure. [2][4]

18. Poor nutritional state
    Children with poor feeding and vomiting may become under-nourished. Lack of calories, vitamins and minerals can further reduce mitochondrial function and make symptoms stronger. [4][6]

19. Prenatal developmental effects
    The MRPL3 defect is present from conception. It can disturb organ development in the womb, especially heart and brain formation. This may partly explain why some babies are already very sick at birth or soon after. [1][3]

20. Unknown additional factors
    For many rare mitochondrial diseases, doctors think there are still unknown biological factors (such as subtle changes in other genes or cell pathways) that can influence disease severity and progression. [4][6]

Symptoms

Not every child will have all of these symptoms, but these are commonly reported in MRPL3-related combined oxidative phosphorylation deficiency. [1][2]

1. Failure to thrive
   The baby does not gain weight or grow as expected, even with normal or extra feeding. Parents may notice loose skin folds, small size for age, and slow growth on the growth chart. [1][3]

2. Poor feeding
   Babies may tire very easily when feeding, drink slowly, or stop before finishing. They may cough or breathe fast during feeds. This can be due to low muscle strength or heart and breathing problems. [2][4]

3. Vomiting or feeding intolerance
   Some babies vomit frequently or seem to be in discomfort after feeding. This can be caused by lactic acidosis, liver involvement, or delayed stomach emptying. [3][5]

4. Low muscle tone (hypotonia)
   The baby may feel “floppy” when lifted, with poor head control and weak limb movements. This happens because the muscles and motor nerves do not have enough energy to work properly. [2][4]

5. Muscle weakness
   As the child grows, weakness can affect sitting, standing or walking. Older infants may not reach milestones on time, such as rolling over or crawling. [2][4]

6. Developmental delay
   The child may learn to smile, sit, talk, or walk much later than other children. In some cases, skills may be lost over time if the disease worsens. [3][5]

7. Psychomotor retardation
   This means the child has both movement and thinking delays. They may have trouble with coordination, problem-solving, and understanding compared to other children of the same age. [1][4]

8. Seizures
   Some children have episodes of abnormal electrical activity in the brain, leading to staring spells, jerking movements, or loss of consciousness. Seizures can be triggered by fever, infection or metabolic stress. [3][5]

9. Hypertrophic cardiomyopathy
   The heart muscle becomes abnormally thick and stiff. This can cause fast breathing, poor feeding, sweating with feeds, swelling of legs or belly, and later heart failure. [1][2]

10. Signs of heart failure
    These include rapid breathing, enlarged liver, poor circulation, cool hands and feet, and poor weight gain. The heart struggles to pump blood effectively because of low energy in heart cells. [2][4]

11. Hepatomegaly (enlarged liver)
    Doctors may feel that the liver is enlarged below the right rib cage. This can be due to fat build-up, congestion from heart failure, or direct mitochondrial damage in liver cells. [3][5]

12. Abnormal liver blood tests
    Blood tests may show raised liver enzymes, low albumin, or abnormal clotting tests. These changes show that the liver is under stress or not working fully. [2][4]

13. Lactic acidosis symptoms
    The child may breathe fast, seem unusually sleepy, or appear very unwell, especially during infections or after fasting. Lactic acid build-up makes the blood more acidic, which can be dangerous. [4][6]

14. Respiratory distress
    Because the heart and muscles are weak and lactic acid is high, breathing can become fast and shallow. Some children need oxygen or ventilatory support in severe stages. [3][5]

15. Early death in severe cases
    In the most severe infantile forms, the combination of heart failure, liver failure, lactic acidosis and infections can lead to death in the first months or years of life, even with good supportive care. [1][2]

Diagnostic tests

Physical examination

1. General physical examination and vital signs
   The doctor carefully looks at the child’s overall appearance, weight, height, head size, breathing rate, heart rate and temperature. In MRPL3-related disease, the child may look thin, small for age and tired, with fast breathing or heart rate. This first exam gives important clues that the child is unwell and may have a serious systemic (whole-body) condition. [1][2]

2. Cardiovascular examination
   The doctor listens to the heart with a stethoscope and checks the pulses, blood pressure, and signs of fluid overload, such as leg swelling or enlarged liver. A thick heart muscle (hypertrophic cardiomyopathy) may cause extra sounds or murmurs. These findings help suggest that the heart is affected, which is common in combined oxidative phosphorylation deficiency. [2][3]

3. Abdominal examination
   The doctor gently feels the abdomen to check the size of the liver and spleen. In many cases, the liver is enlarged and can be felt below the ribs. This can be due to mitochondrial damage in liver cells or congestion from heart failure, both of which are seen in this disease. [3][4]

4. Neurological examination
   The doctor checks muscle tone, strength, reflexes and posture. In MRPL3-related deficiency, babies often have low tone (floppy), weak movements and delayed reflex responses. These signs show that the muscles and nervous system are affected by low energy supply. [2][5]

Manual and bedside tests

5. Growth chart plotting
   The child’s weight, length/height and head size are plotted on standard growth charts. In this disease, the lines may fall below the expected curves, or drop down over time. This pattern of poor growth supports the idea of a chronic energy-related illness, such as a mitochondrial disorder. [1][2]

6. Developmental screening tests
   Simple bedside developmental tools or questionnaires are used to check age-appropriate skills, like smiling, sitting, speaking and walking. Children with combined oxidative phosphorylation deficiency often show delays in several areas (motor, language and social), suggesting an underlying brain and muscle problem. [2][4]

7. Manual muscle strength grading
   The doctor may gently test muscle strength by asking the child (if old enough) to push or pull against resistance, or by observing how the baby holds their head and moves. Reduced strength and easy fatigue during these simple tests support the suspicion of a muscle or mitochondrial disease. [3][5]

Laboratory and pathological tests

8. Blood lactate and pyruvate levels
   A blood sample is taken to measure lactate and sometimes pyruvate. In many mitochondrial diseases, including combined oxidative phosphorylation deficiency, lactate is often high, especially during illness or fasting. A raised lactate level supports the diagnosis of a mitochondrial energy-making problem but is not specific by itself. [1][2]

9. Arterial or venous blood gas analysis
   Blood gas tests measure pH, carbon dioxide, oxygen and bicarbonate. In lactic acidosis, the pH is low (more acidic) and bicarbonate is low, showing metabolic acidosis. This test helps doctors judge how severe the metabolic crisis is and decide on urgent treatment. [2][4]

10. Basic metabolic panel and liver function tests
    Blood tests for sodium, potassium, glucose, urea, creatinine and liver enzymes (ALT, AST, GGT, bilirubin) are done. Abnormal liver enzymes and low blood sugar can be seen in mitochondrial disease. These tests also check kidney and liver function, which may be affected in MRPL3-related deficiency. [3][5]

11. Creatine kinase (CK) and muscle enzymes
    CK and other muscle enzymes may be measured to look for muscle damage. In some mitochondrial diseases CK can be mildly raised, but in others it may be normal. Even if CK is normal, muscle weakness and mitochondrial problems can still be present, so this test is supportive, not definitive. [2][4]

12. Blood and urine organic acids and acylcarnitine profile
    Special metabolic tests measure many small molecules in blood and urine. In mitochondrial disease, certain organic acids and acylcarnitines may be increased, showing that energy pathways are blocked or overloaded. These results help exclude other metabolic diseases and support a mitochondrial defect. [3][6]

13. Full blood count and related tests
    A complete blood count (CBC) can show anemia, low platelets or white cell changes. While not specific, these findings may appear in some mitochondrial diseases and can help assess how sick the child is overall. [4][6]

14. Mitochondrial respiratory chain enzyme analysis
    A biopsy from muscle or skin fibroblasts can be studied in special labs. The activity of complexes I, III, IV and V is measured. In combined oxidative phosphorylation deficiency, several of these complexes show reduced activity, matching the clinical suspicion from genetic and clinical data. [1][2]

15. Muscle or liver biopsy with histology and electron microscopy
    A small sample of muscle or liver may be taken and examined under a microscope and sometimes an electron microscope. Pathologists may see abnormal mitochondria (for example changed size or shape) and other signs of mitochondrial disease. This test is invasive, so it is done only when needed and when it will help clarify the diagnosis. [3][5]

Electrodiagnostic tests

16. Electrocardiogram (ECG)
    An ECG records the heart’s electrical activity. It can show abnormal rhythms, thick heart muscle patterns or conduction problems that accompany hypertrophic cardiomyopathy. In MRPL3-related disease, ECG helps confirm that the heart is structurally and electrically affected by the mitochondrial defect. [1][2]

17. Electroencephalogram (EEG)
    An EEG records electrical activity in the brain. In children with seizures or unexplained spells, the EEG may show abnormal wave patterns, confirming seizure activity or brain dysfunction. This supports the idea that the brain is affected by the mitochondrial energy problem. [3][4]

Imaging tests

18. Echocardiography (heart ultrasound)
    An echocardiogram uses sound waves to create moving pictures of the heart. It can show thickened heart muscle, abnormal pumping, and valve problems. In combined oxidative phosphorylation deficiency 9, echocardiography often reveals hypertrophic cardiomyopathy, which is a key feature of the disease. [1][2]

19. Abdominal ultrasound
    Ultrasound of the abdomen can show an enlarged liver and sometimes changes in liver texture. It also checks for enlarged spleen or fluid in the abdomen. These findings support clinical signs of liver involvement or heart failure in the context of mitochondrial disease. [3][4]

20. Brain MRI and MR spectroscopy
    Magnetic resonance imaging (MRI) of the brain looks at brain structure. It may show delayed myelination, brain atrophy, or lesions in energy-hungry areas like the basal ganglia. MR spectroscopy can measure certain brain chemicals, sometimes showing a lactate peak, which suggests mitochondrial dysfunction. This combination strongly supports a diagnosis of mitochondrial disease when matched with genetic and clinical data. [4][6]

Non-Pharmacological Treatments ( Therapies and Supports)

Because there is no curative medicine, treatment is mainly supportive and multidisciplinary. Many powerful “non-drug” therapies have strong roles in care for COXPD9 and other primary mitochondrial diseases.

1. Multidisciplinary Mitochondrial Clinic Care
Children benefit when neurologists, metabolic specialists, cardiologists, gastroenterologists, dietitians, physiotherapists and psychologists work together in a single coordinated plan. This team approach reduces duplicated tests, speeds responses during crises and ensures that all organ systems are monitored routinely. Families receive clear care plans and emergency letters that explain the child’s condition and special needs to local hospitals and emergency rooms.

2. Genetic Counseling for Family Planning
Genetic counseling helps parents understand the autosomal recessive inheritance of MRPL3-related COXPD9 and the 25% recurrence risk in each pregnancy. Counselors can explain options such as carrier testing of family members, prenatal diagnosis, or preimplantation genetic testing in future pregnancies. This does not change the affected child’s health but can prevent new cases and reduce emotional stress by giving families clear, science-based information.

3. High-Calorie, Energy-Rich Feeding Plans
Because low energy production and illness increase caloric needs, many children with mitochondrial disease require a high-calorie, protein-adequate diet, often with frequent meals or continuous feeds. A metabolic dietitian calculates energy needs and adjusts feeds during illness. The aim is to prevent fasting, weight loss, and catabolism (muscle breakdown), which can worsen lactic acidosis and organ function.

4. Gastrostomy Tube (G-Tube) Feeding Support
When oral feeding is unsafe or insufficient, a G-tube can allow safe delivery of formula or blended diet directly into the stomach. This reduces aspiration risk, makes nighttime continuous feeding possible, and eases the burden of long mealtimes for families. For mitochondrial patients with failure to thrive or aspiration risk, early tube placement can improve growth and reduce hospitalizations for dehydration or malnutrition.

5. Individualised Physiotherapy and Exercise
Gentle, supervised aerobic and resistance exercise can support muscle strength, endurance and mitochondrial biogenesis in many mitochondrial diseases, when tailored carefully to the child’s abilities. Therapy focuses on low-intensity, regularly spaced sessions, with rest breaks and close monitoring for fatigue or muscle pain. Exercise is never “forced”; instead, the goal is to improve function while avoiding over-exertion.

6. Occupational Therapy for Daily Living Skills
Occupational therapists help children learn or adapt daily tasks such as dressing, feeding, writing and playing. They may recommend special seating, splints, or adaptive tools to reduce energy use during tasks. This supports independence, improves school participation and reduces caregiver strain, even when muscle weakness and fatigue are significant.

7. Speech and Swallowing Therapy
Speech and language therapists assess swallowing safety (dysphagia), feeding skills and communication. They may suggest thickened fluids, specific textures, or posture changes to reduce choking and aspiration. They also support early communication through gestures, pictures or devices if speech is delayed, which is common in children with neurodevelopmental involvement.

8. Respiratory Physiotherapy and Airway Clearance
Weak breathing muscles and poor cough can lead to pneumonia. Respiratory physiotherapists teach airway clearance techniques, cough-assist device use, and positioning strategies. Non-invasive ventilation (such as BiPAP) may be introduced during sleep or illness to support breathing and reduce carbon dioxide retention, particularly if there is cardiomyopathy or neuromuscular weakness.

9. Cardiac Lifestyle Management
Children with hypertrophic cardiomyopathy need tailored activity advice and regular cardiology review. Non-pharmacological care includes avoiding dehydration, very heavy exertion, and situations that trigger fainting. Parents learn to monitor for symptoms such as poor feeding, sweating with feeds, fast breathing, or reduced play tolerance. Early recognition of heart failure signs allows prompt medical treatment.

10. Seizure and Emergency Action Plans
For children with seizures or risk of metabolic crises, families are given written emergency plans that explain when to call an ambulance, when to give rescue medicines, and what hospital doctors should do (for example, avoid prolonged fasting and give IV glucose). This planning reduces delays and prevents unsafe treatments, such as certain mitochondrial-toxic drugs.

11. Vaccination and Infection Prevention
Routine and indicated vaccines help reduce serious infections, which are a major trigger for metabolic decompensation in mitochondrial disease. Families are advised on hand-washing, early assessment of fevers, and sometimes prophylactic measures (like flu vaccination of household contacts). The goal is to avoid preventable infections that could stress already fragile organs.

12. Energy Conservation and Pacing Strategies
Occupational and physical therapists teach ways to “pace” activities—breaking tasks into smaller steps, using wheelchairs or strollers for distance, and planning rest periods. This reduces excessive fatigue and helps the child join in school and family activities in a safe, sustainable way, rather than pushing until collapse.

13. Avoidance of Mitochondrial-Toxic Triggers
Several medicines (for example, valproic acid, some aminoglycosides and certain anesthetic agents) can further inhibit respiratory chain function. Mitochondrial guidelines advise avoiding or using them only with extreme caution, and choosing safer alternatives when possible. Fever, dehydration and prolonged fasting are also important triggers to avoid or treat early.

14. Temperature and Illness Management at Home
Parents are taught to treat fevers quickly, encourage liquids, and seek early medical review when the child is vomiting or not feeding. Simple steps such as giving antipyretics as directed, monitoring urine output, and starting emergency feeding plans can reduce hospital admissions and metabolic crises.

15. Developmental and Educational Support
Early intervention programs, special education services and tailored learning plans help children reach their best developmental level. Teachers are informed about fatigue, frequent medical visits and the need for breaks, and adjustments are made for physical, learning or visual difficulties linked to the mitochondrial disease.

16. Psychological Support for Child and Family
Living with a severe rare disease is emotionally tough. Psychologists, social workers and support groups can help parents cope with grief, uncertainty and caregiving stress. Older children benefit from age-appropriate explanations of their condition and support for anxiety or low mood, which are common in chronic illness.

17. Assistive Devices and Orthotics
Wheelchairs, standing frames, ankle–foot orthoses and customized seating can prevent contractures, reduce pain and improve participation in daily life. Proper orthotics support weak muscles and joints, making walking and standing safer and less tiring. Equipment choices are individualized and adjusted as the child grows or as symptoms change.

18. Palliative Care and Symptom-Focused Support
Palliative care is not only for end of life. In mitochondrial disease, these teams help manage pain, breathlessness, feeding difficulties and sleep problems, and support decision-making about invasive treatments. Their aim is to maximise comfort and quality of life alongside ongoing specialist care.

19. Social, Financial and Home-Care Support
Families often need help accessing disability benefits, home nursing, respite care and transportation support. Social workers and patient organisations guide families through these systems, which can greatly reduce stress and help keep the child safely at home instead of in hospital.

20. Reproductive Options (Prenatal and Preimplantation Testing)
For families who wish to avoid recurrence, reproductive options include prenatal testing (chorionic villus sampling or amniocentesis) and preimplantation genetic testing with IVF if the MRPL3 variants are known. These options require careful counseling about benefits, limitations and ethical issues, and are offered at specialised centres.

---

Drug Treatments

There is no specific drug that cures MRPL3-related COXPD9. Medicines are used to:

• support mitochondrial function (cofactor “cocktails”), and

• treat complications (heart failure, seizures, reflux, infections).

Drug information below is based on FDA prescribing data where available, but their use in COXPD9 is usually off-label and must be guided by specialists.

1. Levocarnitine (Carnitor)
Class: Metabolic cofactor.
Purpose: Replaces carnitine and supports fatty-acid transport into mitochondria, especially if blood carnitine is low.
Mechanism: Acts as a carrier molecule that shuttles long-chain fatty acids across the inner mitochondrial membrane for β-oxidation and ATP production.
Use: Given by mouth or IV in weight-based doses as per FDA label, adjusted by metabolic experts.
Side effects: Nausea, diarrhea, fishy body odour, and rarely seizures or arrhythmias; dose and levels need monitoring.

2. Riboflavin (Vitamin B2)
Class: Water-soluble vitamin, cofactor.
Purpose: Supports complexes I and II of the respiratory chain, sometimes improving function in riboflavin-responsive mitochondrial diseases.
Mechanism: Converted to FAD/FMN, which are coenzymes for many redox enzymes in the OXPHOS chain.
Use: Oral doses divided through the day; exact dose depends on age and weight.
Side effects: Usually mild (yellow urine, occasional GI upset).

3. Thiamine (Vitamin B1)
Class: Vitamin cofactor.
Purpose: Supports pyruvate dehydrogenase and other enzymes, helping pyruvate enter the Krebs cycle instead of turning into lactate.
Mechanism: As thiamine pyrophosphate, it is a coenzyme in carbohydrate metabolism, potentially reducing lactic acidosis.
Use: Oral or IV, especially during acute metabolic decompensation.
Side effects: Rare; high doses can cause mild GI upset or, very rarely, allergic reactions with IV use.

4. Coenzyme Q10 (Ubiquinone)
Class: Lipid-soluble antioxidant and electron carrier.
Purpose: Supports electron transfer between complexes I/II and III, and may improve muscle symptoms in some mitochondrial disorders.
Mechanism: Accepts and donates electrons in the respiratory chain and stabilises membranes against oxidative damage.
Use: Taken orally in divided doses; bioavailability can vary.
Side effects: Usually mild (GI upset, appetite changes); may interact with warfarin.

5. Alpha-Lipoic Acid
Class: Antioxidant cofactor.
Purpose: Scavenges free radicals and regenerates other antioxidants, potentially protecting mitochondria from oxidative stress.
Mechanism: Functions as a cofactor for mitochondrial dehydrogenases and improves redox balance.
Use: Oral supplement; dosing is individualized.
Side effects: GI upset, skin rash, possible hypoglycemia in diabetics.

6. Arginine (and Citrulline)
Class: Amino acids; metabolic modifiers.
Purpose: In some mitochondrial disorders (e.g., MELAS), arginine may help treat or prevent stroke-like episodes; similar rationale is sometimes considered in other severe mitochondrial diseases.
Mechanism: Precursor for nitric oxide, improving vascular dilation and blood flow.
Use: Oral or IV under specialist supervision.
Side effects: GI upset, low potassium, low blood pressure if infused quickly.

7. Folinic Acid (Leucovorin)
Class: Reduced folate.
Purpose: Used when cerebrospinal fluid folate is low or when secondary folate problems are suspected in mitochondrial disease.
Mechanism: Bypasses some folate metabolism steps and supports one-carbon transfer reactions important for DNA repair and mitochondrial function.
Side effects: Usually mild; possible GI upset, insomnia or irritability.

8. Vitamin C and Vitamin E
Class: Antioxidant vitamins.
Purpose: Help neutralise reactive oxygen species and protect cell membranes from oxidative damage related to mitochondrial dysfunction.
Mechanism: Vitamin C acts in the aqueous phase; vitamin E protects lipid membranes, working together to reduce oxidative injury.
Side effects: High doses may cause GI upset or, rarely, increased kidney stone risk (vitamin C).

9. Multivitamin Infusions (e.g., Infuvite)
Class: Parenteral multivitamin preparations.
Purpose: Provide balanced vitamins (including B-vitamins) intravenously when enteral intake is poor, preventing deficiencies that can worsen mitochondrial function.
Mechanism: Replace multiple vitamin cofactors required in mitochondrial enzymes, especially during critical illness when needs are increased.
Side effects: Infusion reactions are rare; careful dosing is needed in liver or kidney disease.

10. Standard Heart-Failure Medicines (ACE Inhibitors, Beta-Blockers, Diuretics)
Class: Cardiovascular drugs such as ACE inhibitors (e.g., enalapril), beta-blockers (e.g., carvedilol) and diuretics (e.g., furosemide).
Purpose: Treat hypertrophic cardiomyopathy and heart failure commonly seen in combined OXPHOS deficiency.
Mechanism: Improve cardiac output, reduce fluid overload and lower cardiac workload.
Side effects: Low blood pressure, kidney function changes, electrolyte disturbance; dosing must be closely supervised by cardiology.

11. Anti-Seizure Medicines (e.g., Levetiracetam)
Class: Antiepileptic drugs.
Purpose: Control seizures and prevent repeated brain injury, using agents that are considered relatively mitochondrial-friendly.
Mechanism: Levetiracetam modulates synaptic neurotransmitter release; other agents act on sodium channels or GABA receptors.
Side effects: Behaviour changes, sleepiness, rash; choice of drug avoids those known to worsen mitochondrial function.

12. Benzodiazepines for Rescue (e.g., Diazepam, Midazolam)
Class: GABA-enhancing sedative / anticonvulsant drugs.
Purpose: Used as emergency rescue medicines during prolonged or cluster seizures to protect the brain.
Mechanism: Enhance GABA-mediated inhibition in the brain, rapidly stopping seizure activity.
Side effects: Drowsiness, low breathing rate, risk of dependence with repeated frequent use; always given under medical guidance.

13. Proton Pump Inhibitors (PPIs)
Class: Acid-suppressing drugs.
Purpose: Reduce reflux, esophagitis and aspiration risk in children needing high-calorie feeds or G-tube feeding.
Mechanism: Block gastric proton pumps to reduce acid production.
Side effects: Long-term use may be linked to infections or mineral malabsorption; duration should be reviewed regularly.

14. Antiemetics (e.g., Ondansetron)
Class: 5-HT3 receptor antagonists and others.
Purpose: Control vomiting during infections or metabolic crises to prevent dehydration and allow enteral feeds.
Mechanism: Block serotonin receptors in the gut and brain’s vomiting center.
Side effects: Constipation, headache, QT-interval prolongation at high doses.

15. Intravenous Glucose and Electrolyte Solutions
Class: IV fluids (not classic “drugs” but prescription therapies).
Purpose: Prevent catabolism and hypoglycemia during acute illness by providing immediate energy and correcting dehydration and acidosis.
Mechanism: Supplies glucose directly to blood, sparing muscle protein breakdown and improving acid–base balance when combined with monitored electrolytes.
Side effects: Risk of abnormal sodium or glucose levels if not carefully monitored.

16. Bicarbonate / Buffering Agents
Class: Alkalinizing agents.
Purpose: Correct severe metabolic acidosis when lactate is high and pH is low, as judged by intensive-care teams.
Mechanism: Bicarbonate binds hydrogen ions, raising blood pH.
Side effects: Over-correction of pH, sodium overload, fluid shifts; only used under close monitoring.

17. Broad-Spectrum Antibiotics When Needed
Class: Antibacterial drugs.
Purpose: Treat serious bacterial infections quickly, because infections are major triggers of metabolic decompensation and organ failure in mitochondrial disease.
Mechanism: Kill or inhibit bacterial growth, depending on class.
Side effects: Allergic reactions, gut flora changes, and sometimes kidney or ear toxicity; choices avoid known mitochondrial toxins where possible.

18. Vaccines (as Prescription Biologic Products)
Class: Immunobiologic agents.
Purpose: Protect against infections like influenza, pneumococcus and others that can be particularly dangerous in COXPD9.
Mechanism: Train the immune system to recognise and fight germs quickly.
Side effects: Common short-term side effects include fever, soreness and tiredness; serious reactions are rare compared to the risk of natural infection.

19. Nutritional Formulae and Special Feeds
Class: Medical foods / specialised formulas.
Purpose: Provide balanced nutrition, sometimes with modified fat or protein content, to match the child’s metabolic profile and tolerance.
Mechanism: Deliver energy, essential fatty acids, amino acids and micronutrients in easily digestible form through oral or tube feeding.
Side effects: Taste intolerance, diarrhea or constipation if not well matched to the child.

20. Experimental / Trial Medicines
Class: Various (e.g., novel antioxidants, gene-targeted therapies).
Purpose: Some clinical trials in mitochondrial disease test new antioxidants or agents designed to support mitochondrial biogenesis or reduce oxidative stress. No specific disease-modifying drug is yet approved for MRPL3-related COXPD9.
Mechanism and side effects: Depend on the specific trial drug; participation is only through regulated clinical studies with strict safety monitoring.

---

Dietary Molecular Supplements

Supplements are often used as part of a “mitochondrial cocktail.” Evidence varies, and combinations must be chosen by specialists to avoid interactions and cost without benefit.

1. Coenzyme Q10 – Supports electron transport and acts as an antioxidant; typical dosing is divided across the day with fat-containing meals to improve absorption.

2. L-Carnitine (Oral) – Helps transport long-chain fatty acids into mitochondria; doses are weight-based, similar to levocarnitine drug dosing but given as a supplement when labelled as such.

3. Riboflavin – Supports complex I/II function; often used in moderate to high doses in mitochondrial disease under supervision.

4. Thiamine – Enhances carbohydrate metabolism and may reduce lactate accumulation.

5. Niacin / NAD⁺ Precursors – Support redox balance and NAD⁺-dependent mitochondrial enzymes; human data in mitochondrial disease are still limited.

6. Alpha-Lipoic Acid – Provides antioxidant support and may improve mitochondrial enzyme function.

7. Creatine Monohydrate – Acts as an energy buffer in muscle; some studies in mitochondrial disease suggest improvements in exercise tolerance.

8. Arginine / Citrulline – Support nitric oxide production and vascular function, especially in disorders prone to stroke-like events.

9. Omega-3 Fatty Acids – May support heart and brain health and reduce inflammation; used as supportive, not disease-specific, therapy.

10. Broad Multivitamin / Mineral Supplement – Covers general micronutrient needs, ensuring that no common deficiency (such as vitamin D, iron or zinc) further worsens energy production.

---

Immune-Booster, Regenerative and Stem-Cell-Related Drugs

Currently there are no approved stem-cell or gene-replacement drugs specifically for MRPL3-related COXPD9. Research is ongoing in mitochondrial gene therapy and techniques like protofection, but these remain experimental.

1. Immunoglobulin Replacement (IVIG) in Selected Patients – If a child also has antibody deficiency or recurrent infections, IVIG can support the immune system, decreasing infection-triggered decompensation.

2. Hematopoietic Growth Factors (e.g., G-CSF) – Rarely used if there is significant neutropenia or marrow suppression due to medications or associated conditions, helping reduce infection risk; not specific to MRPL3 but sometimes relevant in complex cases.

3. Exercise-Induced Mitochondrial Biogenesis – Not a drug, but supervised endurance and resistance training can stimulate new mitochondria and improve muscle oxidative capacity, functioning as a “physiologic regenerative therapy.”

4. Experimental Mitochondrial Gene-Targeted Therapies – Research laboratories are exploring techniques to deliver healthy mitochondrial DNA or nuclear gene corrections, but these are not yet available as clinical drugs.

5. Cell-Based Regenerative Approaches (Pre-Clinical) – Some studies investigate stem-cell-derived tissues or organoids to understand mitochondrial disease and test therapies, but direct stem-cell treatment of COXPD9 is still experimental.

6. Clinical Trials with Novel Antioxidants / Mitochondrial Modulators – A few clinical trials in primary mitochondrial disease test drugs aiming to enhance mitochondrial biogenesis or reduce oxidative injury; participation offers access to cutting-edge regenerative strategies, but risks and benefits must be carefully explained.

---

Surgeries (Procedures and Why They Are Done)

1. Gastrostomy Tube Placement – To secure safe, long-term feeding when oral intake is inadequate or unsafe. It reduces aspiration, improves nutrition, and allows continuous night feeds to stabilise energy levels.

2. Fundoplication (Anti-Reflux Surgery) – Sometimes combined with G-tube if severe reflux causes aspiration or pain. Tightening the valve between stomach and oesophagus reduces reflux episodes and lung complications.

3. Cardiac Device Implantation (Pacemaker / ICD) – In selected children with serious rhythm problems or risk of sudden cardiac death due to cardiomyopathy, devices may stabilise heart rhythm and prevent fatal arrhythmias.

4. Orthopaedic Procedures (e.g., Scoliosis Surgery) – If muscle weakness leads to severe spinal curvature or contractures, surgery can improve sitting balance, lung capacity, and pain control.

5. Organ Transplant (Heart or Liver) in Highly Selected Cases – For some mitochondrial diseases with predominant heart or liver failure, transplant may be considered after deep specialist evaluation. For MRPL3-related COXPD9, experience is extremely limited and risks may be high, so decisions are very individualised.

---

Prevention Strategies

Although we cannot fully prevent genetic disease in an affected child, several steps may reduce risk for future children and lower complications in the current patient.

1. Carrier Testing and Genetic Counseling for Parents and Siblings.

2. Prenatal Diagnosis or Preimplantation Genetic Testing for Future Pregnancies.

3. Avoidance of Mitochondrial-Toxic Medications When Alternatives Exist.

4. Routine and Catch-Up Vaccination to Prevent Infections.

5. Early Treatment of Fevers and Infections to Prevent Crises.

6. Avoidance of Prolonged Fasting; Use of Emergency Sick-Day Plans.

7. Regular Cardiac, Liver and Neurologic Monitoring to Catch Problems Early.

8. Planned Anesthesia with Mitochondrial-Aware Teams for Any Surgery.

9. Optimised Nutrition with High-Calorie, Balanced Diet as Advised by a Dietitian.

10. Early Developmental Support to Prevent Secondary Complications of Immobility and Delay.

---

When to See a Doctor

Parents or caregivers should seek urgent medical care if the child has:

• breathing difficulty, fast breathing, or bluish lips;

• seizures or episodes of unresponsiveness;

• very poor feeding, repeated vomiting, or no urine for 6–8 hours;

• sudden swelling, very fast heart rate, or extreme tiredness;

• high fever, especially if different from usual infections.

Regular follow-up with a mitochondrial specialist, cardiologist, neurologist and dietitian is essential even when the child seems stable, because heart, liver or developmental problems can silently progress.

---

Diet: What to Eat and What to Avoid

Diet must always be personalised, but some general principles are commonly used in primary mitochondrial disease care.

Helpful to Eat (Under Dietitian Guidance)

1. Frequent, Balanced Meals and Snacks – To prevent fasting and keep blood sugar stable.

2. Complex Carbohydrates such as whole grains, potatoes, rice, and fruits to provide steady energy.

3. Adequate Protein from meat, fish, eggs, dairy, legumes to support muscle repair and growth.

4. Healthy Fats (olive oil, avocados, nuts, seeds) as energy-dense fuel, if tolerated.

5. Fluids and Electrolytes to prevent dehydration, especially during illness.

Better to Avoid or Limit

1. Prolonged Fasting or Crash Diets, which push the body into catabolic state and worsen energy failure.
2. Very High Simple-Sugar Snacks Only, which give quick spikes then crashes in energy rather than stable support.
3. Excessively High-Fat “Fad” Diets Without Specialist Input, as they may overload fatty-acid oxidation pathways.
4. Alcohol in Older Patients, as it can worsen liver and mitochondrial function (not relevant for young children but important later).
5. Unsupervised High-Dose Supplements bought online, which may interact with prescribed medicines or be contaminated.

---

Frequently Asked Questions (FAQs)

1. Is there a cure for MRPL3-related combined oxidative phosphorylation deficiency?
No specific cure exists at this time. Treatment is supportive: optimising nutrition, treating heart and liver problems, controlling seizures, and using mitochondrial “cocktail” therapies when appropriate. Research into gene and mitochondrial therapies is active but still experimental.

2. How rare is this condition?
MRPL3-related COXPD9 is extremely rare; only a small number of patients have been reported worldwide. Because it is so rare, doctors often rely on general mitochondrial disease guidelines and experience with similar combined OXPHOS defects.

3. Can two healthy parents have a child with this disease?
Yes. In autosomal recessive conditions, both parents carry one faulty MRPL3 gene but are usually healthy. When both pass the faulty copy to a baby, the child is affected. Genetic counselling helps families understand these risks.

4. Will all children in the family be affected?
No. For each pregnancy of two carriers, there is a 25% chance the child will be affected, 50% chance the child will be a healthy carrier, and 25% chance the child will inherit two working copies of the gene.

5. Why does my child tire so easily?
Mitochondria in muscle cells cannot produce enough ATP, so muscles reach fatigue quickly. Exercise and physiotherapy programs are carefully designed to improve endurance without over-working the muscles.

6. Are “mitochondrial cocktails” proven to work?
Some components like coenzyme Q10, carnitine and certain vitamins have supportive evidence in mitochondrial disease, but responses vary and high-quality trials are limited. They are usually tried because they are relatively safe and biologically plausible, but they are not guaranteed cures.

7. Can my child exercise safely?
Yes, in many cases – but exercise must be supervised and individually tailored. Research suggests that carefully increased endurance and resistance exercise can improve mitochondrial function and symptoms for many patients, while over-exertion can be harmful.

8. Why are infections so dangerous?
Fever and infections greatly increase energy needs and may reduce feeding, pushing the body into severe energy shortage. This can trigger lactic acidosis, heart failure or seizures, so quick treatment and supportive care during infections are vital.

9. Is anaesthesia safe in mitochondrial disease?
Many patients undergo anesthesia safely, but some drugs may stress mitochondria. Anesthesia should be planned with teams familiar with mitochondrial disease, and fasting times minimised. A detailed peri-operative plan reduces risks.

10. Can diet alone treat this condition?
Diet cannot fix the underlying gene defect, but good nutrition is essential to avoid worsening energy shortage. High-calorie, balanced diets, avoiding fasting, and using supplements when advised can make a big difference in growth and strength.

11. What is the long-term outlook (prognosis)?
Because so few patients are known, prognosis is hard to predict. Some infants have severe disease and early death; others may live longer with intensive supportive care. Regular specialist follow-up is the best way to anticipate complications and plan care.

12. Can siblings be tested even if they are healthy?
Yes. Carrier or predictive testing may be offered to older siblings and relatives after careful genetic counselling, especially for future family planning.

13. Are vaccines safe for children with COXPD9?
In general, vaccines are recommended and considered safe, because the risk from natural infections is much higher. Inactivated vaccines do not cause disease; live vaccines require individual assessment.

14. Should we join a clinical trial?
Clinical trials can offer access to new treatments and help advance science, but they may also have unknown risks. Families should discuss trial details carefully with their mitochondrial team, including goals, side-effects, and time demands.

15. Where can we find reliable information and support?
Reliable information usually comes from mitochondrial disease centres, genetics clinics and recognised patient organisations. Many guidelines and educational booklets are freely available from mitochondrial foundations and medical journals, which your care team can recommend.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: February 24, 2025.